446 related articles for article (PubMed ID: 29871848)
1. Development of the first small molecule histone deacetylase 6 (HDAC6) degraders.
Yang K; Song Y; Xie H; Wu H; Wu YT; Leisten ED; Tang W
Bioorg Med Chem Lett; 2018 Aug; 28(14):2493-2497. PubMed ID: 29871848
[TBL] [Abstract][Full Text] [Related]
2. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W
Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286
[TBL] [Abstract][Full Text] [Related]
3. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.
Yang X; Wang Z; Pei Y; Song N; Xu L; Feng B; Wang H; Luo X; Hu X; Qiu X; Feng H; Yang Y; Zhou Y; Li J; Zhou B
Eur J Med Chem; 2021 Jun; 218():113341. PubMed ID: 33780898
[TBL] [Abstract][Full Text] [Related]
4. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
Wu H; Yang K; Zhang Z; Leisten ED; Li Z; Xie H; Liu J; Smith KA; Novakova Z; Barinka C; Tang W
J Med Chem; 2019 Aug; 62(15):7042-7057. PubMed ID: 31271281
[TBL] [Abstract][Full Text] [Related]
5. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
6. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
7. Chemo-proteomics exploration of HDAC degradability by small molecule degraders.
Xiong Y; Donovan KA; Eleuteri NA; Kirmani N; Yue H; Razov A; Krupnick NM; Nowak RP; Fischer ES
Cell Chem Biol; 2021 Oct; 28(10):1514-1527.e4. PubMed ID: 34314730
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a fluorescent probe with HDAC6 selective inhibition.
Zhang Y; Yan J; Yao TP
Eur J Med Chem; 2017 Dec; 141():596-602. PubMed ID: 29102179
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of NLRP3 Inflammasome Activation by Indirubin-Derived PROTAC Targeting HDAC6.
Cao Z; Gu Z; Lin S; Chen D; Wang J; Zhao Y; Li Y; Liu T; Li Y; Wang Y; Lin H; He B
ACS Chem Biol; 2021 Dec; 16(12):2746-2751. PubMed ID: 34860497
[TBL] [Abstract][Full Text] [Related]
10. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
Sinatra L; Yang J; Schliehe-Diecks J; Dienstbier N; Vogt M; Gebing P; Bachmann LM; Sönnichsen M; Lenz T; Stühler K; Schöler A; Borkhardt A; Bhatia S; Hansen FK
J Med Chem; 2022 Dec; 65(24):16860-16878. PubMed ID: 36473103
[TBL] [Abstract][Full Text] [Related]
11. A novel class of small molecule inhibitors of HDAC6.
Inks ES; Josey BJ; Jesinkey SR; Chou CJ
ACS Chem Biol; 2012 Feb; 7(2):331-9. PubMed ID: 22047054
[TBL] [Abstract][Full Text] [Related]
12. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
13. PROTAC-mediated crosstalk between E3 ligases.
Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
[TBL] [Abstract][Full Text] [Related]
14. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
Cosenza M; Pozzi S
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30096875
[TBL] [Abstract][Full Text] [Related]
15. Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.
Su S; Yang Z; Gao H; Yang H; Zhu S; An Z; Wang J; Li Q; Chandarlapaty S; Deng H; Wu W; Rao Y
J Med Chem; 2019 Aug; 62(16):7575-7582. PubMed ID: 31330105
[TBL] [Abstract][Full Text] [Related]
16. Small Molecule Antagonists of the Interaction between the Histone Deacetylase 6 Zinc-Finger Domain and Ubiquitin.
Harding RJ; Ferreira de Freitas R; Collins P; Franzoni I; Ravichandran M; Ouyang H; Juarez-Ornelas KA; Lautens M; Schapira M; von Delft F; Santhakumar V; Arrowsmith CH
J Med Chem; 2017 Nov; 60(21):9090-9096. PubMed ID: 29019676
[TBL] [Abstract][Full Text] [Related]
17. Innovative Strategies for Selective Inhibition of Histone Deacetylases.
Maolanon AR; Madsen AS; Olsen CA
Cell Chem Biol; 2016 Jul; 23(7):759-768. PubMed ID: 27447046
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide.
Zhang F; Wu Z; Chen P; Zhang J; Wang T; Zhou J; Zhang H
Bioorg Med Chem; 2020 Jan; 28(1):115228. PubMed ID: 31813613
[TBL] [Abstract][Full Text] [Related]
19. HDAC6 Modulates Signaling Pathways Relevant to Synaptic Biology and Neuronal Differentiation in Human Stem-Cell-Derived Neurons.
Iaconelli J; Xuan L; Karmacharya R
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30935091
[TBL] [Abstract][Full Text] [Related]
20. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
